nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.08.2009 | Original Paper

Mitochondrial DNA content in paired normal and cancerous breast tissue samples from patients with breast cancer

verfasst von: Alex Xiu-Cheng Fan, Ramin Radpour, Mahdi Montazer Haghighi, Corina Kohler, Peng Xia, Sinuhe Hahn, Wolfgang Holzgreve, Xiao Yan Zhong

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 8/2009

Einloggen, um Zugang zu erhalten

Abstract

Introduction

We develop a multiplex quantitative real-time PCR for synchronized analysis of mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) to investigate relative mtDNA abundance in paired normal and cancerous breast tissues.

Materials and methods

The amounts of nDNA and mtDNA in 102 tissue samples were quantified for both glyceraldehype-3-phosphodehydrogenase (GAPDH) gene and mtDNA encoded ATPase (MTATP) 8 gene. The average threshold cycle (Ct) number values of the nDNA and mtDNA were used to calculate relative mtDNA content in breast tissues.

Results

The median delta Ct (ΔCt) and the median mtDNA content for normal and cancerous breast tissues were 6.73 and 2.54, as well as 106.50 and 5.80 (P = 0.000, respectively). The mtDNA content was decreased in 82% of cancerous breast tissues compared with the normal ones. The changes were associated with hormone receptor status.

Conclusion

Our finding suggests that decreased mtDNA content in breast cancer may have diagnostic and prognostic value for the disease.

Bai RK, Leal SM, Covarrubias D, Liu A, Wong LJ (2007) Mitochondrial genetic background modifies breast cancer risk. Cancer Res 67:4687–4694. doi:10.1158/0008-5472.CAN-06-3554 PubMedCrossRef

Buffenstein R, Poppitt SD, McDevitt RM, Prentice AM (1995) Food intake and the menstrual cycle: a retrospective analysis, with implications for appetite research. Physiol Behav 58:1067–1077. doi:10.1016/0031-9384(95)02003-9 PubMedCrossRef

Chen JQ, Delannoy M, Cooke C, Yager JD (2004) Mitochondrial localization of ERalpha and ERbeta in human MCF7 cells. Am J Physiol Endocrinol Metab 286:E1011–E1022. doi:10.1152/ajpendo.00508.2003 PubMedCrossRef

Chen JQ, Yager JD, Russo J (2005) Regulation of mitochondrial respiratory chain structure and function by estrogens/estrogen receptors and potential physiological/pathophysiological implications. Biochim Biophys Acta 1746:1–17. doi:10.1016/j.bbamcr.2005.08.001 PubMedCrossRef

Chen Z, Lu W, Garcia-Prieto C, Huang P (2007) The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr 39:267–274. doi:10.1007/s10863-007-9086-x PubMedCrossRef

Copeland WC, Wachsman JT, Johnson FM, Penta JS (2002) Mitochondrial DNA alterations in cancer. Cancer Invest 20:557–569. doi:10.1081/CNV-120002155 PubMedCrossRef

Ellinger J, Muller SC, Wernert N, von Ruecker A, Bastian PJ (2008) Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy. BJU Int 102(5):628–632PubMedCrossRef

Fontenay M, Cathelin S, Amiot M, Gyan E, Solary E (2006) Mitochondria in hematopoiesis and hematological diseases. Oncogene 25:4757–4767. doi:10.1038/sj.onc.1209606 PubMedCrossRef

Higuchi M (2007) Regulation of mitochondrial DNA content and cancer. Mitochondrion 7:53–57. doi:10.1016/j.mito.2006.12.001 PubMedCrossRef

Jain KK (2007) Cancer biomarkers: current issues and future directions. Curr Opin Mol Ther 9:563–571PubMed

Kim MM, Clinger JD, Masayesva BG, Ha PK, Zahurak ML, Westra WH et al (2004) Mitochondrial DNA quantity increases with histopathologic grade in premalignant and malignant head and neck lesions. Clin Cancer Res 10:8512–8515. doi:10.1158/1078-0432.CCR-04-0734 PubMedCrossRef

Lebrecht D, Kokkori A, Ketelsen UP, Setzer B, Walker UA (2005) Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J Pathol 207:436–444. doi:10.1002/path.1863 PubMedCrossRef

Mambo E, Chatterjee A, Xing M, Tallini G, Haugen BR, Yeung SC et al (2005) Tumor-specific changes in mtDNA content in human cancer. Int J Cancer 116:920–924. doi:10.1002/ijc.21110 PubMedCrossRef

Masuyama M, Iida R, Takatsuka H, Yasuda T, Matsuki T (2005) Quantitative change in mitochondrial DNA content in various mouse tissues during aging. Biochim Biophys Acta 1723:302–308PubMed

Mehra N, Penning M, Maas J, van Daal N, Giles RH, Voest EE (2007) Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer. Clin Cancer Res 13:421–426. doi:10.1158/1078-0432.CCR-06-1087 PubMedCrossRef

Meierhofer D, Mayr JA, Foetschl U, Berger A, Fink K, Schmeller N et al (2004) Decrease of mitochondrial DNA content and energy metabolism in renal cell carcinoma. Carcinogenesis 25:1005–1010. doi:10.1093/carcin/bgh104 PubMedCrossRef

Mizumachi T, Suzuki S, Naito A, Carcel-Trullols J, Evans TT, Spring PM et al (2008a) Increased mitochondrial DNA induces acquired docetaxel resistance in head and neck cancer cells. Oncogene 27:831–838. doi:10.1038/sj.onc.1210681 PubMedCrossRef

Mizumachi T, Naito MLA, Furusawa J, Fan CY, Siegel ER et al (2008b) Increased distributional variance of mitochondrial DNA content associated with prostate cancer cells as compared with normal prostate cells. Prostate 68:408–417. doi:10.1002/pros.20697 PubMedCrossRef

Mosquera-Miguel A, Alvarez-Iglesias V, Carracedo A, Salas A, Vega A, Carracedo A et al (2008) Is mitochondrial DNA variation associated with sporadic breast cancer risk? Cancer Res 68:623–625. doi:10.1158/0008-5472.CAN-07-2385 author reply 624PubMedCrossRef

Penta JS, Johnson FM, Wachsman JT, Copeland WC (2001) Mitochondrial DNA in human malignancy. Mutat Res 488:119–133. doi:10.1016/S1383-5742(01)00053-9 PubMedCrossRef

Rossignol R, Gilkerson R, Aggeler R, Yamagata K, Remington SJ, Capaldi RA (2004) Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res 64:985–993. doi:10.1158/0008-5472.CAN-03-1101 PubMedCrossRef

Simonnet H, Alazard N, Pfeiffer K, Gallou C, Beroud C, Demont J et al (2002) Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 23:759–768. doi:10.1093/carcin/23.5.759 PubMedCrossRef

Tseng LM, Yin PH, Chi CW, Hsu CY, Wu CW, Lee LM et al (2006) Mitochondrial DNA mutations and mitochondrial DNA depletion in breast cancer. Genes Chromosomes Cancer 45:629–638. doi:10.1002/gcc.20326 PubMedCrossRef

Wang Y, Liu VW, Xue WC, Tsang PC, Cheung AN, Ngan HY (2005) The increase of mitochondrial DNA content in endometrial adenocarcinoma cells: a quantitative study using laser-captured microdissected tissues. Gynecol Oncol 98:104–110. doi:10.1016/j.ygyno.2005.04.015 PubMedCrossRef

Webb P (1986) 24-hour energy expenditure and the menstrual cycle. Am J Clin Nutr 44:614–619PubMed

Yager JD, Chen JQ (2007) Mitochondrial estrogen receptors—new insights into specific functions. Trends Endocrinol Metab 18:89–91. doi:10.1016/j.tem.2007.02.006 PubMedCrossRef

Ye C, Shu XO, Wen W, Pierce L, Courtney R, Gao YT et al (2008) Quantitative analysis of mitochondrial DNA 4977-bp deletion in sporadic breast cancer and benign breast diseases. Breast Cancer Res Treat 108:427–434. doi:10.1007/s10549-007-9613-9 PubMedCrossRef

Yin PH, Lee HC, Chau GY, Wu YT, Li SH, Lui WY et al (2004) Alteration of the copy number and deletion of mitochondrial DNA in human hepatocellular carcinoma. Br J Cancer 90:2390–2396PubMed

Yu MZY, Shi Y, Ning L, Yang Y, Wei X et al (2007) Reduced mitochondrial DNA copy number is correlated with tumor progression and prognosis in Chinese breast cancer patients. IUBMB Life 59:450–457. doi:10.1080/15216540701509955 PubMedCrossRef

Zhang XN, Qi M (2008) Mitochondrion and its related disorders: making a comeback. J Zhejiang Univ Sci B 9:90–92. doi:10.1631/jzus.B0710621 PubMedCrossRef

Zhang SP, Song SJ, Li YX (2008) Association between mitochondrial DNA mutations and cancer in human. Yi Chuan 30:263–268. doi:10.3724/SP.J.1005.2008.00263 PubMed

Titel: Mitochondrial DNA content in paired normal and cancerous breast tissue samples from patients with breast cancer
verfasst von: Alex Xiu-Cheng Fan
Ramin Radpour
Mahdi Montazer Haghighi
Corina Kohler
Peng Xia
Sinuhe Hahn
Wolfgang Holzgreve
Xiao Yan Zhong
Publikationsdatum: 01.08.2009
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 8/2009
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-008-0533-9

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Mitochondrial DNA content in paired normal and cancerous breast tissue samples from patients with breast cancer